Share
Four University of California medical centers — San Diego, San Francisco, Irvine, and Davis — have begun recruiting participants for a Phase III clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir.
Remdesivir Is an Antiviral Drug
Remdesivir belongs to a class of antiviral drugs that inhibit RNA-dependent RNA polymerase, an enzyme necessary for some RNA viruses like SARS-CoV-2 to replicate.
Inhibiting the enzyme may prevent viral replication in infected cells.
440 Participants in Trial
The trial is projected to run to April 1, 2023, and will ultimately involve an estimated 440 participants. It is sponsored by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health.
The UC trial will begin with a small group of participants. All must be hospitalized patients with diagnosed COVID-19. All must be patients of UC San Diego Health or other participating UC health systems.
Research is Evolving and Fluid
“Due to the evolving, fluid nature of this research and what we’re learning daily about the virus and about improving treatment, the trial is designed to be adaptive, to shift investigation to the most promising avenues,” said co-principal investigator Constance Benson, MD, professor of medicine at UC San Diego School of Medicine and an infectious disease specialist at UC San Diego Health.
https://www.facebook.com/UCSanDiego/posts/10158210447994781?__tn__=-R
RELATED TOPICS:
CA Has Seen Many New Towns, but This Big Project Is Stalled
1 hour ago
Fresno Man Sentenced to 29 Years for Sexually Assaulting Children and Dog
13 hours ago
Bulldogs’ Two-Position Standout Tommy Hopfe Signs With Rockies
13 hours ago
Former Bulldog QB Jake Haener: I Have a ‘Rare Form of Skin Cancer’
14 hours ago
The Many Names of GOP Vice Presidential Nominee JD Vance
15 hours ago
Jack Black, a Small Dog With a Big Heart, Is Looking for His Forever Home